147808-42-2

Basic information

• Product Name: 5-Bromo-1,3-difluoro-2-nitrobenzene
• Synonyms: 5-bromo-1,3-difluoro-2-nitrobenzene;1-Bromo-3,5-difluoro-4-nitrobenzene;5-Bromo-1,3-difluoro-2-nitrobenzene, 4-Bromo-2,6-difluoronitrobenzene;4-BroMo-2,6-difluoronitrobenzene
• CAS NO: 147808-42-2
• Molecular Formula: C₆H₂BrF₂NO₂
• Molecular Weight: 237.99
• Product Categories: Fluorine series
• Mol File: 147808-42-2.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 266 °C
• Flash Point: 114 °C
• Appearance: /
• Density: 1.890
• Vapor Pressure: 0.0148mmHg at 25°C
• Refractive Index: 1.556
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Bromo-1,3-difluoro-2-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-1,3-difluoro-2-nitrobenzene(147808-42-2)
• EPA Substance Registry System: 5-Bromo-1,3-difluoro-2-nitrobenzene(147808-42-2)

Safety Data

• Hazardous Substances Data: 147808-42-2(Hazardous Substances Data)

Usage

General Description

5-Bromo-1,3-difluoro-2-nitrobenzene is a chemical compound with the molecular formula C6H3BrF2NO2. It is a highly reactive and potentially hazardous compound that is primarily used as an intermediate in the production of pharmaceuticals and agrochemicals. It is known for its strong nitro and bromo groups, which make it useful for various synthetic reactions. However, it should be handled with caution due to its toxic and potentially hazardous properties. It is important to follow proper safety protocols when working with this compound, including using protective equipment and handling it in a well-ventilated area. Overall, 5-Bromo-1,3-difluoro-2-nitrobenzene plays a crucial role in the synthesis of various important chemicals, but its potential hazards must be carefully managed.

InChI:InChI=1/C6H2BrF2NO2/c7-3-1-4(8)6(10(11)12)5(9)2-3/h1-2H

Upstream product

• 5509-65-9 2,6-difluoroaniline 
• 67567-26-4 4-bromo-2,6-difluoroaniline 
• 122129-79-7 4-amino-2,6-difluoronitrobenzene 

Downstream Products

• 797047-10-0 1-(5-bromo-3-fluoro-2-nitrophenyl)-1H-pyrazole 
• 1213262-09-9 C₁₀H₁₂BrFN₂O₃ 
• 1224373-47-0 C₁₁H₁₅BrFN₃O₂ 

Relevant articles and documents

Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a ]quinoxalines

Herein we report the synthesis of fluorinated inhibitors of phosphodiesterase 10A (PDE10A) which can be used potentially as lead structure for the development of a 18F-labeled PDE10A imaging agent for positron emission tomography. The use of or

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

The present invention discloses compounds according to Formula I: wherein Cy, R1, L1, R3, R4, R5, La, and Ra are as defined herein. Novel benzimidazoles according to Formula I, a

Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: Structure-based design and in vivo reduction of amyloid β-peptides

Structure-based design of a series of cyclic hydroxyethylamine BACE1 inhibitors allowed the rational incorporation of prime- and nonprime-side fragments to a central core template without any amide functionality. The core scaffold selection and the structure-activity relationship development were supported by molecular modeling studies and by X-ray analysis of BACE1 complexes with various ligands to expedite the optimization of the series. The direct extension from P1-aryl- and heteroaryl moieties into the S3 binding pocket allowed the enhancement of potency and selectivity over cathepsin D. Restraining the design and synthesis of compounds to a physicochemical property space consistent with central nervous system drugs led to inhibitors with improved blood-brain barrier permeability. Guided by structure-based optimization, we were able to obtain highly potent compounds such as 60p with enzymatic and cellular IC50 values of 2 and 50 nM, respectively, and with >200-fold selectivity over cathepsin D. Pharmacodynamic studies in APP51/16 transgenic mice at oral doses of 180 μmol/kg demonstrated significant reduction of brain Aβ levels.